**Core tip:** Pancreatic hyperechogenicity is related to aging. Several recent studies have reported that hepatic steatosis and increased body mass index (BMI) are predictors of a hyperechogenic pancreas. In the present study, fatty liver was also significantly associated with pancreatic hyperechogenicity. We performed additional analyses excluding participants with fatty liver in order to account for the effect of this condition. Our analyses showed that an increased BMI, higher homeostasis model assessment of insulin resistance score, and decreased adiponectin were also significantly associated with pancreatic hyperechogenicity.

INTRODUCTION
============

Pancreatic hyperechogenicity may be related to the aging process\[[@B1]-[@B3]\]. Previous studies have reported that increased echogenicity of the pancreas is associated with pancreatic lipomatosis\[[@B4],[@B5]\]. Additionally, recent ultrasound studies have demonstrated pancreatic hyperechogenicity is correlated with obesity, hepatic steatosis\[[@B6],[@B7]\], and insulin resistance\[[@B8]\]. To our knowledge, there are a limited number of reports examining the relationship between pancreatic hyperechogenicity and lifestyle-related risk factors.

Recent studies have demonstrated that adipose tissue not only stores fat but also functions as an endocrine organ by producing various adipocytokines such as adiponectin. Adiponectin is a peptide hormone that plays a key role in the development of insulin resistance associated with metabolic syndrome\[[@B9]\]. Adiponectin levels are correlated directly with insulin sensitivity and are decreased in obese individuals and patients with type 2 diabetes\[[@B10],[@B11]\]. Recent studies have shown that there is an association between low concentrations of adiponectin and cancer development\[[@B12],[@B13]\]. However, no report has examined the relationship between adiponectin concentration and pancreatic hyperechogenicity.

The aim of the present study was to examine the associations between pancreatic hyperechogenicity and risk factors for metabolic syndrome, including adiponectin concentration, in the general Japanese population.

MATERIALS AND METHODS
=====================

Study population
----------------

The study was part of an ongoing molecular epidemiological project utilizing the regional characteristics of the 21^st^ Century Centers of Excellence program in Japan, which has been previously described\[[@B14]\]. The surveyed population was the entire population of adults aged over 40 year in the town of Takahata, Yamagata prefecture, located in northeastern Japan. There were 551 participants enrolled in the study between 2005 and 2006. All participants received a physical examination, blood tests, a 75-g oral glucose tolerance test (OGTT), and abdominal ultrasonography (US). We excluded 79 of the 551 participants for the following reasons: Poor US images of the pancreas (43 individuals); blood samples collected in a non-fasting state (27 individuals); or OGTT-diagnosed diabetes mellitus based on the American Diabetes Association criteria (9 individuals)\[[@B15]\]. Exclusion criteria included a history of diabetes or pancreatic disease. However, no participants met the exclusion criteria. The data collected from 472 subjects (201 males and 271 females) were included in the final analysis.

Measurements
------------

We obtained information on current medication and lifestyle-related characteristics from all participants using a questionnaire. Trained study staff measured height, weight and systolic and diastolic blood pressure (BP) using standard methods. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters squared). Insulin resistance was evaluated using the homeostasis model assessment of insulin resistance (HOMA-IR) method with the following equation: HOMA-IR = fasting insulin (μU/mL) × fasting glucose (mg/dL)/405. Venous blood was drawn the morning after an overnight fast. The serum and plasma were separated immediately and stored at -80 °C until analysis. The serum adiponectin concentrations were measured by an enzyme-linked immunosorbent assay as described previously\[[@B9]\]. The other biochemical blood parameters were determined by standard laboratory procedures in the General Laboratory of BML, Inc. (Saitama, Japan). All laboratory personnel were blinded to the status of the samples.

All participants underwent US and an OGTT during a single visit at the research center and within 2 mo of the physical examination and initial blood collection. Blood samples were obtained to determine plasma glucose in the basal period and 120 min after an oral glucose load in the morning following an overnight fast.

The participants fasted overnight for the US study, and the scans were performed by one of four experienced operators using either a Toshiba Nemio^TM^ scanner or an Aloka SSD-3500 scanner with a 3.5-MHz convex transducer. The participants were scanned while lying supine. The images were recorded on a standard computer hard disk drive. The recorded images were analyzed and judged simultaneously by four experienced physicians blinded to the details of the subjects, as described in a previous report\[[@B5]\]. The echogenicity of the pancreatic body was compared with the liver. The subjects were separated into cases with pancreatic echogenicity higher than hepatic echogenicity (*n* = 208) and controls whose pancreatic echogenicity was equal to or lower than the liver (*n* = 264). The presence of fatty liver was defined as a US pattern consistent with evidence of increased ultrasonographic contrast between the hepatic and renal parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins. We used these criteria to divide the subjects into cases with (*n* = 206) or without (*n* = 266) fatty liver.

Statistical analysis
--------------------

The distribution of the continuous variables was assessed for normality. If a normal distribution was evident, then the data were expressed as the means ± standard deviation. The data with a non-normal distribution were log-transformed for analysis and expressed as the median with 25^th^/75^th^ percentiles. The case and control groups were compared using the unpaired *t* test or Fisher's exact test. The relationship between pancreatic hyperechogenicity and clinical and biochemical parameters was determined using multiple logistic regression analyses with the backward elimination method. The odds ratio (OR) and 95%CI were then calculated.

The parameters in the multiple logistic regression analysis were categorized using the following cutoff values: BMI (\< 25 kg/m^2^, ≥ 25 kg/m^2^), systolic BP (\< 130 mmHg, ≥ 130 mmHg), diastolic BP (\< 85 mmHg, ≥ 85 mmHg), fasting plasma glucose (\< 110 mg/dL, ≥ 110 mg/dL), HOMA-IR score (\< 2.0, ≥ 2.0), high-density lipoprotein (HDL) cholesterol (\< 40 mg/dL, ≥ 40 mg/dL), triglyceride (\< 150 mg/dL, ≥ 150 mg/dL), glutamic pyruvic transaminase (GPT) (\< 35 IU/L, ≥ 35 IU/L), pre-load plasma glucose in the OGTT (\< 110 mg/dL, ≥ 110 mg/dL) and post-load 2-h plasma glucose in the OGTT (\< 140 mg/dL, ≥ 140 mg/dL). The median values for serum insulin and pancreatic isoamylase were used as the cutoff points. Serum adiponectin was analyzed as a continuous variable. All data were analyzed using SPSS software (version 15.0, SPSS Inc., Chicago, IL, United States). All differences with *P* \< 0.05 were considered statistically significant. The statistical methods of this study were reviewed by Yuko Nishise from the Faculty of Medicine, Yamagata University.

RESULTS
=======

The baseline clinical and biochemical data for the cases and controls are shown in Table [1](#T1){ref-type="table"}. The serum adiponectin levels were markedly lower in the cases than in the controls \[8.9 (6.5-12.8) *vs* 11.1 (7.8-15.9), *P* \< 0.001\]. In addition, there were significant differences between the cases and controls for the following variables: Age, presence of fatty liver, weight, BMI, systolic BP, diastolic BP, serum insulin, fasting plasma glucose, HOMA-IR score, HDL cholesterol, total cholesterol, triglyceride, pancreatic isoamylase, GPT, preload plasma glucose in the OGTT, and 2-h plasma glucose.

###### 

Comparison of baseline characteristics between the pancreatic hyperechogenicity and control groups

  **Clinical parameters**                        **Pancreatic hyperechogenicity (*n* = 208)**   **Controls (*n* = 264)**   ***P* value**
  ---------------------------------------------- ---------------------------------------------- -------------------------- ---------------
  Age (yr)                                       60.8 ± 9.4                                     56.9 ± 9.8                 \< 0.001
  Fatty liver (fatty/non-fatty)                  113/95                                         93/171                     \< 0.001
  Sex (male/female)                              86/122                                         115/149                    0.640
  Height (cm)                                    157.9 ± 8.4                                    159.3 ± 8.8                0.085
  Weight (kg)                                    61.2 ± 9.4                                     56.2 ± 9.3                 \< 0.001
  BMI (kg/m^2^)                                  24.4 ± 2.6                                     22.1 ± 2.7                 \< 0.001
  Systolic BP (mmHg)                             135.9 ± 15.8                                   129.6 ± 15.7               \< 0.001
  Diastolic BP (mmHg)                            83.1 ± 10.2                                    79.6 ± 10.2                \< 0.001
  Adiponectin (μg/mL)                            8.9 (6.5-12.8)                                 11.1 (7.8-15.9)            \< 0.001
  Serum insulin (μU/mL)                          4.7 (3.4-6.8)                                  3.6 (2.7-5.0)              \< 0.001
  Fasting plasma glucose (mg/dL)                 94.5 ± 9.2                                     90.8 ± 9.7                 \< 0.001
  HOMA-IR                                        1.1 (0.7-1.6)                                  0.8 (0.6-1.1)              \< 0.001
  High-density lipoprotein cholesterol (mg/dL)   58.4 ± 14.2                                    63.2 ± 15.4                0.001
  Low-density lipoprotein cholesterol (mg/dL)    127.1 ± 36.1                                   123.8 ± 32.4               0.310
  Total cholesterol (mg/dL)                      205.9 ± 33.1                                   199.8 ± 34.4               0.049
  Triglyceride (mg/dL)                           96 (71-135)                                    81 (63-112)                \< 0.001
  Pancreatic isoamylase (U/L)                    28 (23-34)                                     30 (25-37)                 0.014
  Glutamic oxaloacetic transaminase (IU/L)       23 (20-27)                                     22 (19-28)                 0.706
  Glutamic pyruvic transaminase (IU/L)           21 (17-28)                                     20 (15-26)                 0.011
  γ-glutamyl transpeptidase (IU/L)               24 (17-42)                                     22 (15-33)                 0.070
  Preload plasma glucose (OGTT) (mg/dL)          97.4 ± 9.9                                     93.1 ± 10.2                \< 0.001
  2-h plasma glucose (OGTT) (mg/dL)              114.6 ± 29.7                                   101.1 ± 26.7               \< 0.001

Data are expressed as means ± SD, or median (25^th^; 75^th^ percentiles). Unpaired *t* test or Fisher's exact test were used to compare the two groups. BMI: Body mass index; BP: Blood pressure; HOMA-IR: Homeostasis model assessment of insulin resistance; OGTT: Oral glucose tolerance test.

Each parameter was dichotomized according to the cutoff points to further explore the relationship between pancreatic hyperechogenicity and other parameters. We then conducted multiple logistic regression analyses with the backward elimination method.

We first used an age-adjusted model to exclude the influence of aging. The results indicate that there was a significant negative association between decreased adiponectin levels and pancreatic hyperechogenicity (OR = 0.92, 95%CI: 0.88-0.95, *P* \< 0.001). In addition, the presence of fatty liver, higher values of BMI, systolic BP, diastolic BP, serum insulin, HOMA-IR score, 2-h plasma glucose and lower pancreatic isoamylase levels were significantly associated with pancreatic hyperechogenicity (Table [2](#T2){ref-type="table"}).

###### 

Age-adjusted and multivariate odds ratios for pancreatic hyperechogenicity

  **Confounding factor**                                                    **Pancreatic hyperechogenicity (*n*)**   **Controls (*n*)**   **Age-adjusted**   **Multivariate[3](#T2FN3){ref-type="table-fn"}**                      
  ------------------------------------------------------------------------- ---------------------------------------- -------------------- ------------------ -------------------------------------------------- ------------------ ----------
  Non-fatty liver/fatty liver                                               95/113                                   171/93               2.6 (1.8-3.9)      \< 0.001                                           1.77 (1.15-2.72)   0.009
  BMI (kg/m^2^), \< 25/≥ 25                                                 125/83                                   229/35               5.0 (3.1-8.0)      \< 0.001                                           3.56 (2.17-5.83)   \< 0.001
  Systolic BP (mmHg), \< 130/≥ 130                                          60/148                                   119/145              1.6 (1.1-2.5)      0.016                                                                 
  Diastolic BP (mmHg), \< 85/≥ 85                                           110/98                                   180/84               1.9 (1.3-2.7)      0.001                                                                 
  Adiponectin (μg/mL)[1](#T2FN1){ref-type="table-fn"}                                                                                     0.92 (0.88-0.95)   \< 0.001                                           0.9 (0.91-0.98)    0.004
  Serum insulin (μU/mL)[2](#T2FN2){ref-type="table-fn"}, ≤ 4.0/\> 4.0       83/125                                   153/111              2.2 (1.5-3.2)      \< 0.001                                                              
  Fasting plasma glucose (mg/dL), \< 110/≥ 110                              198/10                                   251/13               0.8 (0.3-1.9)      0.593                                                                 
  HOMA-IR, \< 2.0/≥ 2.0                                                     177/31                                   253/11               4.4 (2.1-9.1)      \< 0.001                                           2.4 (1.1-5.1)      0.032
  HDL cholesterol (mg/dL), ≥ 40/\< 40                                       194/14                                   253/11               1.9 (0.8-4.5)      0.119                                                                 
  Triglyceride (mg/dL), \< 150/≥ 150                                        173/35                                   234/30               1.7 (1.0-2.9)      0.055                                                                 
  Pancreatic isoamylase (U/L)[2](#T2FN2){ref-type="table-fn"}, ≥ 30/\< 30   89/119                                   143/121              1.7 (1.2-2.5)      0.004                                              2.08 (0.95-4.57)   0.068
  GPT (IU/L), \< 35/≥ 35                                                    177/31                                   234/30               1.7 (1.0-2.9)      0.069                                                                 
  Preload plasma glucose (OGTT) (mg/dL), \< 110/≥ 110                       189/19                                   247/17               1.1 (0.6-2.3)      0.710                                                                 
  2-h plasma glucose (OGTT) (mg/dL), \< 140/≥ 140                           170/38                                   244/20               2.4 (1.3-4.3)      0.003                                                                 

Serum adiponectin was analyzed as a continuous variable;

The median values for serum insulin and pancreatic isoamylase were used as the cutoff points;

Adjusted for the age, presence of fatty liver, BMI, systolic BP, diastolic BP, adiponectin, serum insulin, HOMA-IR, triglyceride, pancreatic isoamylase, GPT and 2-h plasma glucose. Odds ratios and 95%CI were estimated using the multiple logistic regression model with backward elimination. BMI: Body mass index; BP: Blood pressure; HOMA-IR: Homeostasis model assessment of insulin resistance; HDL: High-density lipoprotein; GPT: Glutamic pyruvic transaminase; OGTT: Oral glucose tolerance test.

We next performed the analysis after adjustment for age, presence of fatty liver, BMI, systolic and diastolic BP, adiponectin, serum insulin, HOMA-IR, triglyceride, pancreatic isoamylase, GPT, and 2-h plasma glucose. The analysis showed that hypoadiponectinemia was significantly associated with pancreatic hyperechogenicity (OR = 0.9, 95%CI: 0.91-0.98, *P* = 0.004), independent of the other confounding variables. The presence of fatty liver, increased BMI, and higher HOMA-IR score were also significantly associated with pancreatic hyperechogenicity. In addition, decreased pancreatic isoamylase showed a weak relationship with pancreatic hyperechogenicity (Table [2](#T2){ref-type="table"}).

We then performed further analyses to exclude the influence of fatty liver. The baseline clinical and biochemical data for cases and controls without fatty liver are shown in Table [3](#T3){ref-type="table"}. The serum adiponectin levels were lower in cases than in controls \[10.3 (7.6-14.6) *vs* 12.0 (8.6-17.0), *P* = 0.022\]. Furthermore, there were significant differences between cases and controls for the following parameters: Age, weight, BMI, serum insulin, fasting plasma glucose, HOMA-IR score, HDL cholesterol, triglycerides, and preload plasma glucose in the OGTT.

###### 

Comparison of baseline characteristics between the pancreatic hyperechogenicity and control groups excluding participants with fatty liver

  **Clinical parameters**                        **Pancreatic hyperechogenicity (*n* = 95)**   **Control (*n* = 171)**   ***P* value**
  ---------------------------------------------- --------------------------------------------- ------------------------- ---------------
  Age (yr)                                       62 ± 9                                        58 ± 10                   0.001
  Sex (male/female)                              44/51                                         76/95                     0.769
  Height (cm)                                    158.0 ± 8.0                                   158.1 ± 9.0               0.960
  Weight (kg)                                    59.5 ± 9.4                                    53.9 ± 8.5                \< 0.001
  BMI (kg/m^2^)                                  23.7 ± 2.6                                    21.5 ± 2.5                \< 0.001
  Systolic BP (mmHg)                             133 ± 17                                      130 ± 16                  0.135
  Diastolic BP (mmHg)                            82 ± 11                                       80 ± 10                   0.180
  Adiponectin (μg/mL)                            10.3 (7.6-14.6)                               12.0 (8.6-17.0)           0.022
  Serum insulin (μU/mL)                          4.0 (2.7-5.4)                                 3.3 (2.5-4.5)             0.004
  Fasting plasma glucose (mg/dL)                 93 ± 8                                        90 ± 10                   0.026
  HOMA-IR                                        0.9 (0.59-1.28)                               0.71 (0.54-1.02)          0.002
  High-density lipoprotein cholesterol (mg/dL)   60 ± 15                                       66 ± 15                   0.001
  Low-density lipoprotein cholesterol (mg/dL)    124 ± 35                                      122 ± 33                  0.708
  Total cholesterol (mg/dL)                      202 ± 33                                      199 ± 36                  0.464
  Triglyceride (mg/dL)                           87 (66-133)                                   76 (59-96)                0.005
  Pancreatic isoamylase (U/L)                    29 (24-35)                                    31 (25-37)                0.054
  Glutamic oxaloacetic transaminase (IU/L)       22 (19-25)                                    23 (19-28)                0.189
  Glutamic pyruvic transaminase (IU/L)           19 (16-23)                                    20 (15-25)                0.937
  γ-glutamyl transpeptidase (IU/L)               21 (16-40)                                    21 (15-32)                0.266
  Preload plasma glucose (OGTT) (mg/dL)          96 ± 9                                        92 ± 10                   0.009
  2-h plasma glucose (OGTT) (mg/dL)              107 ± 29                                      100 ± 28                  0.063

Data are expressed as means ± SD, or median (25^th^; 75^th^ percentiles). Unpaired *t* test or Fisher's exact test were used to compare the two groups. BMI: Body mass index; BP: Blood pressure; HOMA-IR: Homeostasis model assessment of insulin resistance; OGTT: Oral glucose tolerance test.

We next performed multivariate association analyses of data from participants without fatty liver. The multivariate analysis showed that hypoadiponectinemia was significantly associated with pancreatic hyperechogenicity (OR = 0.93, 95%CI: 0.90-0.97, *P* \< 0.001), independent of the other confounding variables. Additionally, an increased BMI and higher HOMA-IR score were also significantly associated with pancreatic hyperechogenicity (Table [4](#T4){ref-type="table"}).

###### 

Multivariate association analysis of clinical parameters for pancreatic hyperechogenicity excluding participants with fatty liver

                                                        **Multivariate[2](#T4FN2){ref-type="table-fn"}**   
  ----------------------------------------------------- -------------------------------------------------- ----------
  BMI (kg/m^2^)                                         3.89 (2.39-6.35)                                   \< 0.001
  Adiponectin (μg/mL)[1](#T4FN1){ref-type="table-fn"}   0.93 (0.90-0.97)                                   \< 0.001
  HOMA-IR                                               2.23 (1.02-4.89)                                   0.045

Serum adiponectin was analyzed as a continuous variable;

Adjusted for age, BMI, diastolic BP, adiponectin, serum insulin, HOMA-IR, HDL cholesterol, triglyceride and pancreatic isoamylase. Odds ratios and 95%CI were estimated using the multiple logistic regression model with backward elimination. CI: Confidence interval; BMI: Body mass index; HOMA-IR: Homeostasis model assessment of insulin resistance.

DISCUSSION
==========

Studies examining digestive organ disease and altered secretion of adipocytokines caused by metabolic syndrome will improve our understanding of the mechanisms involved in pathophysiological conditions. It is possible that such investigations might lead to the development of preventive measures for diseases linked to metabolic syndrome.

Pancreatic hyperechogenicity is thought to be related to the aging process\[[@B1]-[@B3]\]. Our data showed that several features of metabolic syndrome, such as higher BMI, increased HOMA-IR score, and hypoadiponectinemia, were also independently associated with pancreatic hyperechogenicity.

This is the first study conducted in a general population that investigated the relationship between pancreatic hyperechogenicity and risk factors of metabolic syndrome, such as insulin resistance and serum adiponectin concentration. The main study findings were: (1) that serum adiponectin concentrations were markedly lower in subjects with pancreatic hyperechogenicity than in controls \[8.9 (6.5-12.8) *vs* 11.1 (7.8-15.9), *P* \< 0.001\]; and (2) that decreased adiponectin levels were associated independently with pancreatic hyperechogenicity (OR = 0.9, 95%CI: 0.91-0.98, *P* = 0.004). Adiponectin is produced by adipose tissue, and a low adiponectin concentration is considered to be a key factor in the development of insulin resistance underlying metabolic syndrome\[[@B9]-[@B11]\].

Several studies have reported that increased echogenicity of the pancreas is related to lipomatosis of the pancreatic parenchyma\[[@B4],[@B5]\]. Pancreatic lipomatosis is the most common histological change in the pancreas associated with age, obesity, and insulin resistance\[[@B6]-[@B8],[@B16]-[@B19]\]. Recently, Raeder et al\[[@B5]\] evaluated the pancreatic fat content using US and magnetic resonance imaging and showed that pancreatic lipomatosis may reflect early events involved in the pathogenesis of diabetes and exocrine pancreatic dysfunction in non-diabetic children with mutations in carboxyl-ester lipase. In addition, Tushuizen and co-workers\[[@B20]\] measured the pancreatic fat content using proton magnetic resonance spectroscopy and found that pancreatic fat was inversely associated with β-cell function parameters in non-diabetic men. However, there was no association in their diabetic counterparts. The authors suggested that pancreatic fat content may contribute to β-cell dysfunction\[[@B20]\]. In our logistic regression analysis, we adjusted for age and pancreatic hyperechogenicity, which is a potential marker of lipomatosis. We found that these parameters were associated with higher serum insulin, HOMA-IR, and 2-h plasma glucose levels in the OGTT. There was no association with fasting and preload plasma glucose concentrations in the OGTT (Table [2](#T2){ref-type="table"}). It is possible that pancreatic hyperechogenicity with insulin resistance precedes the development of diabetes in the non-diabetic general population. Thus, further large-scale prospective studies are necessary to investigate whether pancreatic hyperechogenicity is an early pathological event in the diabetes disease process.

Several recent studies have reported that hepatic steatosis and increased BMI are predictors of a hyperechogenic pancreas\[[@B6],[@B7]\]. In the present study, fatty liver was also significantly associated with pancreatic hyperechogenicity (OR = 1.77, 95%CI: 1.15-2.72, *P* = 0.009) (Table [2](#T2){ref-type="table"}). Therefore, we performed additional analyses excluding participants with fatty liver in order to account for the effect of this condition in our results. The adjusted analysis showed that increased BMI, higher HOMA-IR score, and decreased adiponectin were also significantly associated with pancreatic hyperechogenicity (Table [4](#T4){ref-type="table"}). This is the first study investigating the relationship between pancreatic hyperechogenicity and risk factors for metabolic syndrome by excluding the influence of fatty liver.

In this study, we used a simple and traditional method of assessing the severity of pancreatic hyperechogenicity, which was the comparison of echogenicity between the pancreatic body and the liver. However, this approach can potentially result in misdiagnosis of pancreatic hyperechogenicity if the extent of fatty liver is severe. We also performed additional analyses to exclude the influence of fatty liver. As shown in Tables [2](#T2){ref-type="table"} and [4](#T4){ref-type="table"}, the results of our analyses that either included or excluded fatty liver, respectively, were similar and both showed increased BMI, higher HOMA-IR scores, and decreased adiponectin levels. However, our study had a limitation: No histological confirmation of pancreatic fat was possible.

There may be unknown factors that may cause the histological changes associated with obesity in addition to fat accumulation, fibrosis and functional changes in the exocrine pancreas. We recently demonstrated that intra-lobular fat accumulates in exocrine pancreatic tissue and that lipid droplets in acinar cells increase in Zucker diabetic fatty rats, which is an animal model of type 2 diabetes caused by the chronic intake of a high-fat diet. These conditions appear cause acinar cell injury and fibrosis\[[@B21]\]. Thus, additional clinical and experimental studies of the interrelationships between diabetes, metabolic syndrome and pancreatic injury should be conducted to clarify the pathogenesis of "non-alcoholic fatty pancreatic disease".

In conclusion, our study of a non-diabetic general population showed that pancreatic hyperechogenicity was independently associated with increased BMI, insulin resistance and hypoadiponectinemia.
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